Cargando…
The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials
OBJECTIVE: To characterize the financial toxicity experienced by advanced cancer patients enrolled in phase I oncology trials. PATIENTS AND METHODS: We conducted structured interviews with cancer patients participating in phase I clinical trials. Using a thematic analysis approach, we identified rec...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685144/ https://www.ncbi.nlm.nih.gov/pubmed/38035050 http://dx.doi.org/10.1016/j.mayocpiqo.2023.09.003 |
_version_ | 1785151563847696384 |
---|---|
author | Williams, Colt Meyer, Leigh Kawam, Omar Leventakos, Konstantinos DeMartino, Erin S. |
author_facet | Williams, Colt Meyer, Leigh Kawam, Omar Leventakos, Konstantinos DeMartino, Erin S. |
author_sort | Williams, Colt |
collection | PubMed |
description | OBJECTIVE: To characterize the financial toxicity experienced by advanced cancer patients enrolled in phase I oncology trials. PATIENTS AND METHODS: We conducted structured interviews with cancer patients participating in phase I clinical trials. Using a thematic analysis approach, we identified recurring themes in patients’ experiences of financial toxicity resulting from trial participation. RESULTS: Seven major themes emerged from the interviews: (1) the burden of travel, (2) a willingness to pursue treatment despite financial risk, (3) fear of destitution, (4) financial toxicity equaling physical toxicity, (5) changes in food spending, (6) reluctance to confide in the study investigator about financial toxicity, and (7) difficulty navigating financial aid. These themes highlight the multifaceted financial challenges faced by patients in early phase clinical trials and the need for targeted support services. CONCLUSION: Our findings underscore the relevance of financial toxicity in the context of phase I clinical trials and provide insights into the diverse challenges faced by advanced cancer patients. These challenges likely augment the disparities seen in trial enrollment for historically marginalized populations. Addressing financial toxicity in this population is crucial for improving patient outcomes and quality of life. Future research should focus on developing effective interventions and support services tailored to the needs of patients in early phase clinical trials. |
format | Online Article Text |
id | pubmed-10685144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-106851442023-11-30 The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials Williams, Colt Meyer, Leigh Kawam, Omar Leventakos, Konstantinos DeMartino, Erin S. Mayo Clin Proc Innov Qual Outcomes Original Article OBJECTIVE: To characterize the financial toxicity experienced by advanced cancer patients enrolled in phase I oncology trials. PATIENTS AND METHODS: We conducted structured interviews with cancer patients participating in phase I clinical trials. Using a thematic analysis approach, we identified recurring themes in patients’ experiences of financial toxicity resulting from trial participation. RESULTS: Seven major themes emerged from the interviews: (1) the burden of travel, (2) a willingness to pursue treatment despite financial risk, (3) fear of destitution, (4) financial toxicity equaling physical toxicity, (5) changes in food spending, (6) reluctance to confide in the study investigator about financial toxicity, and (7) difficulty navigating financial aid. These themes highlight the multifaceted financial challenges faced by patients in early phase clinical trials and the need for targeted support services. CONCLUSION: Our findings underscore the relevance of financial toxicity in the context of phase I clinical trials and provide insights into the diverse challenges faced by advanced cancer patients. These challenges likely augment the disparities seen in trial enrollment for historically marginalized populations. Addressing financial toxicity in this population is crucial for improving patient outcomes and quality of life. Future research should focus on developing effective interventions and support services tailored to the needs of patients in early phase clinical trials. Elsevier 2023-11-15 /pmc/articles/PMC10685144/ /pubmed/38035050 http://dx.doi.org/10.1016/j.mayocpiqo.2023.09.003 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Williams, Colt Meyer, Leigh Kawam, Omar Leventakos, Konstantinos DeMartino, Erin S. The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials |
title | The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials |
title_full | The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials |
title_fullStr | The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials |
title_full_unstemmed | The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials |
title_short | The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials |
title_sort | faces of financial toxicity: a qualitative interview study of financial toxicity in advanced cancer patients in phase i oncology trials |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685144/ https://www.ncbi.nlm.nih.gov/pubmed/38035050 http://dx.doi.org/10.1016/j.mayocpiqo.2023.09.003 |
work_keys_str_mv | AT williamscolt thefacesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials AT meyerleigh thefacesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials AT kawamomar thefacesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials AT leventakoskonstantinos thefacesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials AT demartinoerins thefacesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials AT williamscolt facesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials AT meyerleigh facesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials AT kawamomar facesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials AT leventakoskonstantinos facesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials AT demartinoerins facesoffinancialtoxicityaqualitativeinterviewstudyoffinancialtoxicityinadvancedcancerpatientsinphaseioncologytrials |